Canaani, Jonathan

Publications

Sort by

Co-Author Network

selected publications

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study. Blood advances. 2025 Academic Article GET IT
Times cited: 2
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study. Acta haematologica. 2024 Article GET IT
Times cited: 1
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. British journal of haematology. 2024 Academic Article GET IT
Times cited: 3
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation. Haematologica. 2023 Academic Article GET IT
Times cited: 16
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. European journal of haematology. 2023 Academic Article GET IT
Times cited: 8
Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2023 Academic Article GET IT
The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival. Annals of hematology. 2023 Academic Article GET IT
Times cited: 7
Real-World Efficacy Outcomes of FLT3-ITD^mut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction. Clinical lymphoma, myeloma & leukemia. 2022 Letter GET IT
Times cited: 1
Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding 5 years. European journal of haematology. 2022 Academic Article GET IT
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis. 2022 GET IT
Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Transplantation and cellular therapy. 2022 Academic Article GET IT
Times cited: 3
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of hematology. 2022 Academic Article GET IT
Times cited: 14
Evaluation of the clinical impact of bone marrow cultures in current medical practice. Scientific reports. 2022 Academic Article GET IT
Times cited: 1
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone marrow transplantation. 2022 Academic Article GET IT
Times cited: 7
Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. Annals of hematology. 2022 Academic Article GET IT
Times cited: 6
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy. Annals of hematology. 2022 Academic Article GET IT
Times cited: 5
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation. American journal of hematology. 2022 Academic Article GET IT
Times cited: 4
Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and cellular therapy. 2021 Academic Article GET IT
Times cited: 16
Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
Times cited: 4
Association of Preoperative Clinical, Laboratory, Imaging, and Pathologic Data With Clinically Beneficial Pathology Among Routine Splenectomy Specimens. JAMA network open. 2021 Academic Article GET IT
Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Acta haematologica. 2021 Academic Article GET IT
Times cited: 6
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. American journal of hematology. 2021 Academic Article GET IT
Times cited: 23
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of hematology & oncology. 2021 Academic Article GET IT
Times cited: 62
Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021 Academic Article GET IT
Times cited: 7
A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. European journal of haematology. 2020 Academic Article GET IT
Times cited: 7
Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 32
Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. American journal of hematology. 2020 Academic Article GET IT
Times cited: 7
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. Oncotarget. 2020 Academic Article GET IT
Times cited: 7
Emerging Therapies for the Myelodysplastic Syndromes. Clinical hematology international. 2019 Review GET IT
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. Echocardiography (Mount Kisco, N.Y.). 2019 Academic Article GET IT
Times cited: 8
The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Biochemical pharmacology. 2019 Academic Article GET IT
Times cited: 12
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 70
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood advances. 2019 Academic Article GET IT
Times cited: 61
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer discovery. 2019 Academic Article GET IT
Times cited: 313
Management of AML Beyond "3 + 7" in 2019. Clinical hematology international. 2019 Review GET IT
Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019 Academic Article GET IT
Times cited: 25
A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. Leukemia. 2019 Academic Article GET IT
Times cited: 12
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. Journal of internal medicine. 2018 Academic Article GET IT
Times cited: 34
Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). British journal of haematology. 2018 Academic Article GET IT
Times cited: 32
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone marrow transplantation. 2018 Academic Article GET IT
Times cited: 19
Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. Oncogenesis. 2018 Academic Article GET IT
Times cited: 15
Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone marrow transplantation. 2018 Review GET IT
Times cited: 14
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. European journal of cancer. 2018 Academic Article GET IT
Times cited: 35
T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American journal of hematology. 2018 Academic Article GET IT
Times cited: 20
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. American journal of hematology. 2017 Academic Article GET IT
Times cited: 67
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017 Academic Article GET IT
Times cited: 24
Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. Oncotarget. 2017 Academic Article GET IT
Times cited: 4
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American journal of hematology. 2017 Academic Article GET IT
Times cited: 42
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. American journal of hematology. 2017 Academic Article GET IT
Times cited: 18
Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. American journal of hematology. 2017 Academic Article GET IT
Times cited: 19
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017 Academic Article GET IT
Times cited: 44
Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. American journal of hematology. 2017 Academic Article GET IT
Times cited: 25
Established and emerging targeted therapies in the myelodysplastic syndromes. Expert review of hematology. 2016 Review GET IT
Times cited: 4
Revisiting maintenance therapy in acute myeloid leukemia with novel agents. Current opinion in hematology. 2016 Review GET IT
Times cited: 5
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2015 Letter GET IT
Times cited: 27
MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflammatory bowel diseases. 2013 Academic Article GET IT
Times cited: 70
Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors. Leukemia. 2013 Academic Article GET IT
Times cited: 53
Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma. 2013 GET IT
Times cited: 7
Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia. European journal of haematology. 2012 Letter GET IT
Times cited: 1
Regulatory cross talks of bone cells, hematopoietic stem cells and the nervous system maintain hematopoiesis. Inflammation & allergy drug targets. 2012 Review GET IT
Times cited: 23
FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation. Blood. 2012 Academic Article GET IT
Times cited: 94
Predictive parameters for a diagnostic bone marrow biopsy specimen in the work-up of fever of unknown origin. Mayo Clinic proceedings. 2012 Academic Article GET IT
Times cited: 26
Neural regulation of bone, marrow, and the microenvironment. Frontiers in bioscience (Scholar edition). 2011 Review GET IT
Times cited: 7
Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. Journal of digestive diseases. 2008 Academic Article GET IT
Times cited: 17
Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2008 Academic Article GET IT
Times cited: 5

more ...

less ...

Background

education and training

M.D., Sackler School of Medicine, Tel Aviv University (Israel) 2009
B.Sc., Tel Aviv University (Israel) 2003

Contact

full name

Jonathan Canaani

primary email

ygg9005@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Jonathan Canaani Associate Professor of Medicine (Pending Appointment at Rank)

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage